



AN OVERVIEW ON PHARMACOLOGICAL PROPERTIES OF DIABETES MELLITUS

Mr. Jay Narayan Kumar Saw¹, Mr. Shubham Singh², Ms. Tanya Sharma³

Student of B.pharmacy at Mewar university¹, Gangrar, Chittorgarh (Rajasthan),312901.

Student at deen dayal Rustogi college of pharmacy²Khandwela Distt, Near Haily Mandi (Haryana)122504.

Assistant professor at Mewar University³Gangrar,Chittorgarh (Rajasthan),312901.

Corresponding author: Ms.Tanya Sharma (28taney@gmail.com)

ABSTRACT :

Persistent hyperglycemia caused by abnormalities in insulin release, insulin activity, or both defines a chronic metabolic disease known as diabetes mellitus. Rising occurrence and high morbidity and mortality make it a worldwide health issue. Over the years, the pharmacological treatment of diabetes has changed markedly to cover a broad spectrum of drug classes designed to address different facets of glucose homeostasis. Including insulin therapy, oral hypoglycemic drugs like sulfonylureas, biguanides, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1 receptor agonists, this review points out the main pharmacologic compounds employed in diabetes mellitus treatment. It also talks about the mechanisms of operation, medicinal advantages, and possible negative effects of these medicines. Optimal individualized therapy plans and better patient results depends on knowledge of the pharmacodynamics and pharmacokinetics of antidiabetic drugs. This review underlines how essential are a holistic therapeutic method that links life style adjustment with medicinal therapy for managing diabetes.

keywords: chronic metabolic disorder, diabetes mellitus (DM) ,Insulin Resistance.

Competing interests

The authors declare no conflicts of interest.

1. INTRODUCTION

Definition of Diabetes Mellitus

Chronic hyperglycemia resulting from insulin secretion, insulin resistance, or both is a feature found in a diverse range of conditions known as Diabetes Mellitus (DM) [1]. Essential for the control of glucose metabolism is a hormone made by the beta cells in the pancreatic islets called insulin. Insufficient insulin synthesis or resistance of cells to insulin's effects cause blood glucose levels to rise, therefore long-term problems abound if not handled correctly [2].

One of the most severe and complex public health challenges around the world is diabetes, given its chronic character and the progressive harm it does to essential organs including the heart, blood vessels, eyes, kidneys, and nerves[3].

Need of Knowing Diabetes Risen

One must know diabetes in view of its worldwide health burden, rising incidence, and reversible side effects. In 2021, the International Diabetes Federation (IDF) estimates that 1 in 10 adults had diabetes and nearly 7 million deaths a year were caused by the disease and its complications [4]. Almost half of all adults living with diabetes go undiagnosed; usually early signs are understated or incorrectly attributed [5].

Beyond physical symptoms, diabetes imposes a major fiscal burden on people and healthcare systems. In 2021, global healthcare spending on diabetes was estimated at USD 966 billion, a threefold surge over the past 15 years. Early education and awareness of the disease might help to improve self-management, hasten diagnosis, and enhance healthcare planning.

Understanding diabetes is therefore not only essential for people living with it but also for those in danger and for healthcare providers, legislators, and instructors trying to minimize its impact. Lifestyle changes—among them diet, physical exercise, and weight management—have been shown to reduce the chances of type 2 diabetes by up to 58% in high-risk groups [7].

2. Types of diabetes mellitus

Based on pathophysiology and cause, diabetes is generally divided into four main kinds:

Type 1 diabetes

An autoimmune illness whereby the immune system destroys insulin-generating beta cells in the pancreas, hence causing total insulin deficiency, is type 1 diabetes [8]. Though usually seen in youth or early adulthood, this kind can appear at any time. For survival, people with type 1 diabetes need exogenous insulin.

It is thought that genetic vulnerability and environmental factors including viral infections (enteroviruses, for example) activate the autoimmune response [9]. Type 1 diabetes is deadly in the absence of insulin treatment. Management refers also to constant blood sugar levels checking, diet planning, and physical activity changes [10].

Patients' quality of life and blood glucose control greatly improved when artificial pancreas" and hybrid closed-loop insulin pumps were coupled with advancements like continuous glucose monitoring (CGM) [11].

Type II Diabetes

A slow metabolic condition identified by insulin resistance and a relative insulin shortfall is Type 2 diabetes. Unlike type 1 diabetes, which usually starts suddenly, type 2 diabetes typically develops slowly and is closely tied to lifestyle factors such as obesity, unbalanced diet, and physical inactivity as well as to genetics; it absolutely different hundreds more usual type, making up over 90% of diabetes cases so globally [12].

Cells in muscle, fat, and liver that do not react well to insulin and cannot readily absorb glucose from the blood cause insulin resistance. Hyperglycemia develops when the pancreas fails over time to provide enough insulin to keep usual blood glucose levels [13].

Although some people need insulin, many can control type 2 diabetes with lifestyle adjustments, weight loss, and oral medicines (e.g., metformin). Lifestyle changes can appreciably lower the risk of at-risk people developing type 2 diabetes, according to preventive strategies such as the Diabetes Prevention Program (DPP) [14].

Gestational diabetes condition

First observed during pregnancy, gestational diabetes mellitus (GDM) is a kind of hyperglycaemia usually found in the second or third trimester. It happens because hormonal shifts lead to insulin resistance and raised insulin requirements the pancreas cannot fulfill [15].

Women with GDM run a much higher risk of developing type 2 diabetes later in life—as much as 50% within 5–10 years after delivery, although blood glucose levels usually normalize after delivery [16]. Macrosomia, neonatal hypoglycemia, respiratory distress syndrome, and future obesity or glucose intolerance in childhood are among the fetal hazards associated with GDM [17].

Managing GDM and limiting negative results fundamentally depends on good screening, dietary guidance, glucose tracking, and in certain cases insulin therapy [18].

Other particular varieties

Maturity-Onset Diabetes of the Young (MODY): A collection of monogenic disorders caused in particular genes that affect insulin production mutations. In many cases before age 25, it is often wrongly diagnosed as type 1 or type 2 diabetes [19].

Rising from adulthood in adults is a slow-moving type of autoimmune diabetes that looks like type 1. At first, LADA is often treated as type 2 until insulin is required [20].

Damage to the pancreas (e.g., pancreatitis, cystic fibrosis), hormone imbalances (e.g., Cushing's syndrome), or secondary Diabetes as a result of medicine use including glucocorticoids or antipsychotics [21].

3. Causes and Risk Factors of Diabetes Mellitus

A chronic metabolic disease characterized by high blood sugar levels caused by the body's inability to produce enough insulin or to use insulin properly is diabetes. Diabetes results from several causes, including genetic, behavioral, and environmental factors. These reasons and risk factors are discussed more fully in this essay.

Genetics Factors

The development of Type 1 and Type 2 diabetes is much determined by genetic predisposition.

An autoimmune condition is **Type 1 Diabetes (T1D)**: the immune system assaults and kills insulin-producing beta cells in the pancreas. With the HLA-DR3 and HLA-DR4 haplotypes having the most correlation with the disorder, [22] the genetic aspect of T1D is connected to particular alleles in the human leukocyte antigen (HLA) region. Family history is a strong indicator; children with a parent or sibling suffering T1D are much more likely to develop the disease themselves [23].

Type 2 Diabetes (T2D): T2D shows strong genetic underpinning, and many genes have been linked with greater susceptibility. For example, mutations in the TCF7L2 gene, which affects insulin release, are typically found to be linked to a greater chance of developing T2D [24]. Genomic association studies (GWAS) have found more than 80 loci related with T2D, suggesting that T2D genetic risk is polygenic [25]. In T2D, where a person with one affected parents is twice as high and with both parents the risk might rise five times, family history has even more relevance.[26]

LifeStyle and Environmental stimuli

Particularly Type 2, environmental and lifestyle factors much influence the onset and course of diabetes.

- **Diet:** Developing Type 2 diabetes is a well-known risk factor for a diet rich in calories, processed foods, sugar beverages, and unhealthy fats. Studies reveal that a diet high in red meat and processed meats is linked with a greater likelihood of developing T2D, whereas one rich in fruits, vegetables, whole grains, and lean proteins might help decrease this risk by means of consuming too many refined carbohydrates and sweets raises blood glucose levels and causes insulin resistance over time[27].
- **Physical activity:** Lack of physical activity is another large environmental factor causing insulin resistance; studies have shown that yearning activity even in moderate quantities can considerably reduce the risk of Type 2 diabetes [28]. Physical inactivity causes weight gain and reduced muscle mass, both of which worsen insulin sensitivity.
- **Stress and Sleep:** Higher cortisol levels linked with worse sleep hygiene and constant stress can lower insulin sensitivity and rise blood sugar levels. Furthermore associated with increased blood pressure and inflammation—both of which are risk factors for diabetes—poor sleep has been [29].
- **Environmental Toxins:** Some research are also exploring exposure to environmental toxic substances like endocrine-disrupting compounds—those that interfere with hormone regulation—for their likely link with the growth of diabetes. Chemicals including bisphenol A (BPA) found in plastics have been associated with increased risk of obesity and diabetes in some studies [30].
- **Weight problems and insulin resistance**
- The most important modifiable risk factor for Type 2 diabetes is obesity, especially abdominal or visceral obesity. Abdominal fat especially causes the release of inflammatory cytokines and fatty acids that impede insulin signaling [31]. The adipose tissue creates proteins and hormones that may provoke systemic inflammation which worsens insulin resistance.
- **Insulin resistance:** When muscle, liver, and fat cells become less sensitive to insulin, insulin resistance happens. Consequently these cells do not efficiently absorb glucose, which raises blood glucose levels. Ultimately, this may lead to beta cells in the pancreas being exhausted and lacking. Although genetics and bad lifestyle decisions may also play a part, obesity is the main reason of insulin resistance[32].
- **Body mass index (BMI) and diabetes risk:** The risk of developing Type 2 diabetes increases with body mass index (BMI). A BMI of 25-29.9 kg/m² is considered overweight, and a BMI of 30 kg/m² or higher is classified as obese; people with a BMI greater than 30 are at significantly higher risk for insulin resistance and Type 2 diabetes. Even small weight loss (5-10% of body weight) have been shown in research to dramatically lower the odds of contracting diabetes [33].

4. Signs and Symptoms of Diabetes

Diabetes typically appears slowly and its signs could be somewhat minor initially. Left untreated, though, the symptoms can worsen significantly and result in major issues.

Normally Symptoms

The usual signs of both Type 1 and Type 2 diabetes are:

Polyuria (frequent urination): The kidneys have to work more to filter and absorb the extra glucose when blood sugar is high, which results in polyuria (frequent urination). Dehydration and frequent urination result from this.

Polydipsia (hopeless thirst): Increased urination causes dehydration, which induces people to feel very thirsty; polydipsia (hopeless thirst) is thereby established.

Fatigue: Cells do not get the energy they need because the body cannot use glucose efficiently, therefore causing extreme exhaustion.

Blurred Vision: High blood sugar might result in vision problems by inducing fluid imbalances in the lenses of the eyes.

Slow-healing Wounds: Elevated blood glucose levels damage circulation and the immune system, hence impeding the body's natural wound-healing capacity.

Frequent infections: High glucose levels can damage the immune system, hence increasing vulnerability to infections, particularly skin infections and urinary tract infections [34].

Differences in Symptoms between Type 1 and Type 2 Diabetes

- **Symptoms of Type 1 Diabetes (T1D):** T1D usually develop all at once and advance quickly. T1D sufferers might exhibit symptoms like tiredness, weight loss, frequent urination, and excessive thirst. Usually found in children and young grownups but presentable at any age, T1D is often detected by ketoacidosis, a life-threatening disorder caused by lack of insulin that results in blood ketones accumulation. Nausea, vomiting, belly pain, fruity-smelling breath, and confusion are all symptoms of ketoacidosis [35]. The fast onset of symptoms is frequently associated with it.
- **Developing slowly, Type 2 Diabetes (T2D)** symptoms might remain unobserved for many years. Until problems arise, some people might suffer little symptoms or none at all. Most common in adults over 45, the ailment can affect underage people, particularly those with a family history of diabetes or overweight. Though it might occur in severe instances, T2D is seldom linked with ketoacidosis at diagnosis—unlike T1D [36].

5. Management and Treatment of Diabetes Mellitus

Control of diabetes calls for a three-pronged strategy of medication, lifestyle change, and frequent monitoring.

Living Changes

Diet is a fundamental part of diabetes control. A diet high in whole grains, fruits, vegetables, low fat proteins, and good fats can help regulate blood sugar levels [37]. Better postprandial glucose control can result from low-glycemic index (GI) meals. Mediterranean and DASH diets are connected with enhanced insulin sensitivity and lower cardiovascular risk [38].

Key diet suggestions:

- i. Restrict product of refined carbs and added sugars.
- ii. Raise intake of dietary fiber (25–38 g/day) [39] behind bars.
- iii. Opt unsaturated fats (monounsaturated and polyunsaturated) over saturated and trans fats.

Exercise: Working out helps in weight loss, insulin sensitivity, and cardiovascular risk management goals. The Americans with Disabilities Act suggests:

- i. Three days per week, spread over at least 150 minutes/week of moderate-to-vigorous cardiovascular training. [40].
- ii. To increase muscle mass and insulin use, at least 2–3 sessions a week of resistance training [41].
- iii. In addition to aiding type 2 diabetic patients to lower HbA1c by 0.5 percent to 0.7%, activity helps [42].

Weight Control : Losing 5–10% of body weight can significantly improve glycemic control and decrease insulin resistance [43]. therefore obesity is a major risk factor for type 2 diabetes. Behavioral approaches like calorie counting, goal-setting, and self-monitoring improve weight management efforts. A_score_split 7.

Medicines

Insulin Therapy: All patients with type 1 diabetes absolutely need insulin, as do those with type 2 diabetes who don't get glycemic control with oral medications. Types of insulin are:

- i. Quick (for ex., lispro, aspart)
- ii. Acting briefly (regular insulin)
- iii. Intermediate-release (NPH)
- iv. Long-release (eg, Glargine, Detemir)

Based on lifestyle, patient requirements, and glucose levels, insulin regimens are customized.[44]

Hypoglycemic medicines taken by mouth: Type 2 diabetes can be treated with a few classes of oral medications:

- i. First-line medicine due to effectiveness, safety, and weight neutrality is metformin. [45]
- ii. Sulfonylureas stimulate insulin release (e.g., glipizide) but can also result in hypoglycemia.
- iii. DPP-4 inhibitors: Increase incretin levels (e.g., sitagliptin), therefore stimulating insulin release.
- iv. SGLT2 inhibitors: lowers renal glucose reabsorption which promotes glycosuria (e.g., empagliflozin).
- v. GLP-1 glucagon-like peptide-1 receptor agonists: improved insulin sensitivity, slowed stomach emptying, and increased appetite. [46]

Checking blood glucose levels

Blood Glucose (SGL) Self-Monitoring: Some patients on suinsulins or sulfonylureas ought to monitor their blood sugar to prevent hypoglycemia and change the treatment. Frequency depends on the treatment regimen:

- i. 4 to 10 times every day, type 1 diabetes compiles.
- ii. As advised, especially if on insulin [47]: Type 2 diabetes.

Continuous Glucose Monitoring (CGM): Particularly useful for patients on aggressive insulin regimens, CGM offers live data and helps raise HbA1c and lower glycemic variability [48].

6. Prevention of Diabetes Mellitus

Lifestyle changes aimed at at-risk people are mostly effective in preventing type 2 diabetes.

Eating habits that are healthy

Reducing the occurrence of type 2 diabetes can be achieved by following wise dietary habits. Lower diabetes risk is linked to high fiber intake (especially from whole grains), nuts, fruits, and vegetables [49]. Insulin resistance is lowered and weight is kept under control by diets restricting sugary drinks, refined carbohydrates, and meats that are usually red and processed [50].

The PREDIMED trial showed that a Mediterranean diet without calorie restriction decreased diabetes risk by 30% [51].

Guidelines on Physical Activity: Diabetes prevention depends very much on usual physical activity level.

- i. Enhances sensitivity of insulin.
- ii. Aids with weight management.
- iii. Decreases blood pressure; enhances lipid profile.

The best results are seen from a mix of resistance training and aerobics. Over 3 years, lifestyle intervention according to the Diabetes Prevention Program (DPP) lowered diabetes rates by 58 percent. [52]

Lowering risk factors: Risk for diabetes rises by modifiable factors such as:

- i. Smoking
- ii. Obesity
- iii. Physical inactivity
- iv. Hypertension and dyslipidemia

Smoking Cessation: Stopping smoking boosts cardiovascular health and insulin sensitivity otherwise aggravated by 30-40 percent[53]. Smoking raises

the risk of type 2 diabetes by 30-40%.

Early Screening and Responsive Assistance: Regular screening is advised for those with prediabetes or metabolic syndrome. Interventions at the prediabetes stage can significantly delay or stop disease development.[54]

7. Living with Diabetes

Millions of people globally suffer diabetes, a long-term illness. Maintaining a good quality of living and avoiding complications requires a life-long dedication to self-care and awareness to face diabetes. The state of self-care and daily management, their psychological and social repercussions, and the part of support groups and existing aids are discussed in this post.

Daily handling and self-care

The basis of diabetes therapy is effective self-care. This entails scheduling regular medical appointments, adhering to prescription schedules, having a balanced diet, keeping in shape, and monitoring blood sugar levels.

By means of blood glucose monitoring, people can keep tabs on their condition and make wise choices in terms of diet and medicine. Good glycemic control depends on keeping a balanced diet—high in fiber, low in sugar and saturated fat—physical exercise will help to control blood sugar level and enhance insulin sensitivity [55].

Long-term diabetes management also critically depends on educating patients about kidney health, eye exams, and foot care, as well as on medication adherence—whether it be insulin injections or oral hypoglycemics to prevent complications like neuropathy, retinopathy, and heart disease. [56]

Psychological and social ones

Living with diabetes might be emotionally difficult. The demands of management of the chronic illness frequently lead people to feel anxious, under pressure, or depressed. Research have found that those with diabetes tend to have depression 2–3 times more frequent than people lacking the condition. [57]

How well people control their diabetes depends significantly on their social support. Support from family, friends, or medical professional may lower isolation feelings and encourage compliance with healthy behaviors. Furthermore, in some people, stigma or ignorance about the disease might cause low self-esteem and social withdrawal [58].

For people suffering from diabetes, psychological support—provided through counselling or behavioral therapy—can substantially better the quality of life and medical results.

Counseling Groups and Tools

For those with diabetes, support groups provide means to share stories, techniques of dealing, and counsel. Members are helped in handling their condition more effectively by a sense of community and empowerment they offer.

Online forums and communities have also become more popular, especially among individuals in isolated areas who might not have in-person support available, together with groups like the International Diabetes Federation (IDF) and the American Diabetes Association (ADA) offer valuable resources like educational material, self-management tools, and information on the most recent research and treatments [59].

Including diabetes educators, dieticians, and mental health experts, healthcare professionals can assist patients in finding suitable support groups or resources.

Conclusion

Finally, the pharmacological treatment of diabetes mellitus is critically important for maintaining blood sugar levels and stopping long-term problems linked with the condition. Many antidiabetic medications with different mechanisms of action provide personalized treatment plans based on each patient's needs and comorbidities. Though progress in pharmacotherapy has notably better the quality of life for diabetic patients, obstacles including drug resistance, side effects, and patient compliance persist. Effective and sustainable diabetes control thus calls for a thorough strategy including lifestyle changes, continuous observation, patient education, and pharmacological therapy. Future studies should look on creating more precise and safer therapeutics to improve even more the results of treatment.

REFERENCES

1. American Diabetes Association. (2021). Diagnosis and classification of diabetes mellitus. *Diabetes Care*, 44(S1), S15–S33.
2. World Health Organization. (2021). Diabetes. <https://www.who.int/news-room/fact-sheets/detail/diabetes>
3. Zimmet, P., Alberti, K. G., & Shaw, J. (2001). Global and societal implications of the diabetes epidemic. *Nature*, 414(6865), 782–787.
4. International Diabetes Federation. (2021). *IDF Diabetes Atlas*, 10th edition. <https://diabetesatlas.org>
5. Saedi, P., et al. (2019). Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045. *Diabetes Research and Clinical Practice*, 157, 107843.
6. Bommer, C., et al. (2017). The global economic burden of diabetes in adults aged 20–79 years. *Diabetes Care*, 40(7), 985–993.

7. Knowler, W. C., et al. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *New England Journal of Medicine*, 346(6), 393–403.
8. Atkinson, M. A., Eisenbarth, G. S., & Michels, A. W. (2014). Type 1 diabetes. *The Lancet*, 383(9911), 69–82.
9. Rewers, M., & Ludvigsson, J. (2016). Environmental risk factors for type 1 diabetes. *The Lancet*, 387(10035), 2340–2348.
10. Chiang, J. L., et al. (2018). Type 1 diabetes through the life span: a position statement of the American Diabetes Association. *Diabetes Care*, 37(7), 2034–2054.
11. Foster, N. C., et al. (2019). State of type 1 diabetes management and outcomes from the T1D Exchange in 2016–2018. *Diabetes Technology & Therapeutics*, 21(2), 66–72.
12. DeFronzo, R. A., et al. (2015). Pathogenesis of type 2 diabetes mellitus. *Medical Clinics*, 99(1).
13. Taylor, R. (2012). Type 2 diabetes: etiology and reversibility. *Diabetes Care*, 36(4), 1047–1055.
14. Diabetes Prevention Program Research Group. (2002). The Diabetes Prevention Program (DPP). *New England Journal of Medicine*, 346(6), 393–403.
15. Buchanan, T. A., & Xiang, A. H. (2005). Gestational diabetes mellitus. *The Journal of Clinical Investigation*, 115(3), 485–491.
16. Kim, C., et al. (2002). Risk of type 2 diabetes mellitus after gestational diabetes mellitus. *Diabetes Care*, 25(10), 1862–1868.
17. Landon, M. B., et al. (2009). A multicenter, randomized trial of treatment for mild gestational diabetes. *New England Journal of Medicine*, 361(14), 1339–1348.
18. American College of Obstetricians and Gynecologists (ACOG). (2018). Practice Bulletin No. 190: Gestational Diabetes Mellitus. *Obstetrics & Gynecology*, 131(2), e49–e64.
19. Fajans, S. S., Bell, G. I., & Polonsky, K. S. (2001). Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young (MODY). *New England Journal of Medicine*, 345(13), 971–980.
20. Fourlanos, S., et al. (2005). Latent autoimmune diabetes in adults (LADA) should be less latent. *Diabetologia*, 48(11), 2206–2212.
21. Kaveeshwar, S. A., & Cornwall, J. (2014). The current state of diabetes mellitus in India. *Australasian Medical Journal*, 7(1), 45–48.
22. Noble, J. A., & Valdes, A. M. (2011). Genetics of the HLA region in the prediction of type 1 diabetes. *Current Diabetes Reports*, 11(6), 533–542.
23. Dabelea, D., et al. (2014). Incidence of diabetes in youth in the United States. *JAMA*, 311(17), 1778–1786.
24. Mahajan, A., et al. (2018). Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes. *Nature Genetics*, 50(4), 559–571.
25. Florez, J. C., et al. (2004). TCF7L2 polymorphisms and type 2 diabetes: evidence of gene-diet interaction. *The Lancet*, 364(9444), 1997–2004.
26. Harris, M. I., et al. (1992). Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. *Diabetes Care*, 21(4), 518–524.
27. Hu, F. B., et al. (2001). Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. *New England Journal of Medicine*, 345(11), 790–797.
28. Colberg, S. R., et al. (2016). Physical activity and diabetes: A position statement of the American Diabetes Association. *Diabetes Care*, 39(11), 2065–2079.
29. Spiegel, K., et al. (2005). Sleep loss: a novel risk factor for insulin resistance and Type 2 diabetes. *Journal of Applied Physiology*, 99(5), 2008–2019.
30. Miodovnik, A., et al. (2011). Endocrine-disrupting chemicals and childhood health. *International Journal of Andrology*, 34(3), e39–e52.
31. Kahn, S. E., et al. (2006). Mechanisms linking obesity to insulin resistance and type 2 diabetes. *Nature*, 444(7121), 840–846.
32. Gjesing, A. P., et al. (2012). Insulin resistance in the metabolic syndrome: role of obesity and genetics. *Diabetes Obesity and Metabolism*, 14(9), 806–814.
33. Colditz, G. A., et al. (1995). Weight as a risk factor for clinical diabetes in women. *American Journal of Epidemiology*, 132(3), 501–513.
34. American Diabetes Association. (2023). Symptoms of diabetes. Retrieved from diabetes.org
35. Dabelea, D., et al. (2014). Incidence of diabetes in youth in the United States. *JAMA*, 311(17), 1778–1786.
36. Harris, M. I., et al. (1992). Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. *Diabetes Care*, 21(4), 518–524.
37. Jenkins, D.J. et al. (2002). Glycemic index: overview of implications in health and disease. *Am J Clin Nutr*, 76(1), 266S–273S.
38. Esposito, K. et al. (2010). Mediterranean diet improves endothelial function. *JAMA*, 292(12), 1440–1446.
39. Slavin, J. (2005). Dietary fiber and body weight. *Nutrition*, 21(3), 411–418.
40. ADA. (2023). Standards of Medical Care in Diabetes—2023. *Diabetes Care*, 46(Suppl 1): S68–S96.
41. Colberg, S.R. et al. (2016). Exercise and Type 2 Diabetes. *Diabetes Care*, 39(11), 2065–2079.
42. Thomas, D.E. et al. (2006). Exercise and glycemic control in type 2 diabetes. *Diabetologia*, 49(11), 2370–2382.
43. Knowler, W.C. et al. (2002). DPP Study Group. *N Engl J Med*, 346(6):393–403.
44. Hirsch, I.B. (2005). Insulin analogues. *N Engl J Med*, 352:174–183.
45. UKPDS Group. (1998). Metformin vs conventional therapy. *Lancet*, 352(9131), 854–865.
46. Nauck, M. et al. (2009). Incretin-based therapies. *Diabetes Care*, 32(Suppl 2), S223–S231.
47. American Diabetes Association. (2023). Diabetes Technology. *Diabetes Care*, 46(Suppl 1), S111–S127.
48. Battelino, T. et al. (2019). Time in range consensus. *Diabetes Care*, 42(8), 1593–1603.
49. de Munter, J.S. et al. (2007). Whole grain, bran, and germ intake and risk of type 2 diabetes. *PLoS Med*, 4(8), e261.
50. Schulze, M.B. et al. (2004). Red meat intake and risk of type 2 diabetes. *Diabetes Care*, 27(9), 2108–2115.

51. Salas-Salvadó, J. et al. (2011). PREDIMED-Reus trial. *Diabetes Care*, 34(1), 14–19.
52. Knowler, W.C. et al. (2002). DPP Research Group. *N Engl J Med*, 346(6), 393–403.
53. Willi, C. et al. (2007). Active smoking and the risk of type 2 diabetes: A systematic review and meta-analysis. *JAMA*, 298(22), 2654–2664.
54. Pan, X.R. et al. (1997). Da Qing IGT and Diabetes Study. *Diabetes Care*, 20(4), 537–544.
55. American Diabetes Association. (2022). Standards of Medical Care in Diabetes—2022. *Diabetes Care*, 45(Supplement_1): S1–S264. <https://doi.org/10.2337/dc22-S001>
56. Centers for Disease Control and Prevention (CDC). (2022). Diabetes Medications. <https://www.cdc.gov/diabetes/basics/type2/medication.html>
57. Anderson, R. J., et al. (2001). The prevalence of comorbid depression in adults with diabetes: a meta-analysis. *Diabetes Care*, 24(6), 1069-1078. <https://doi.org/10.2337/diacare.24.6.1069>
58. Schabert, J., Browne, J. L., Mosely, K., & Speight, J. (2013). Social stigma in diabetes: a framework to understand a growing problem for an increasing epidemic. *Patient*, 6(1), 1–10. <https://doi.org/10.1007/s40271-012-0001-0>
59. International Diabetes Federation (IDF). (2023). Resources for People with Diabetes. <https://www.idf.org/>